News | Radiation Therapy | October 24, 2020

RefleXion Highlights New Research at ASTRO 2020

The research evaluates the feasibility of biology-guided radiotherapy to treat metastatic cancer

The research evaluates the feasibility of biology-guided radiotherapy to treat metastatic cancer

October 24, 2020 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced that eight clinical abstracts evaluating the use of its novel technology were accepted for presentation during the virtual American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting, Oct. 24-28.

“We are thrilled to have eight abstracts from leading academic clinicians highlighting our technology,” said Sean Shirvani, M.D., senior vice president of Clinical and Medical Affairs at RefleXion. “The presentations will share new data on the potential of BgRT for targeting tumors in diverse anatomic locations and from varied histologies, including non-small cell lung, prostate and pancreatic cancers. The investigations also explore the exciting opportunity of leveraging PET information as a future biomarker with BgRT.

“Through our clinical partnerships, we continue to produce comprehensive, evidence-based research that builds on the strong foundation of previously published studies,” continued Shirvani. “We believe the RefleXion X1 can form the backbone of any radiotherapy clinic, as it delivers IMRT/SBRT/SRS and unlocks opportunities for procedural growth with BgRT in local and metastatic disease.”

The following presentations taking place during ASTRO 2020 evaluate RefleXion’s novel technology:

Sunday, Oct 25, 2:15 PM. Poster Session 02, Poster Hall:

  • 2686 “Simultaneous Integrated Boost of Lung Tumors in the Stereotactic Ablative Setting using BgRT Tracked Delivery”
  • 2831 “Use of a Detailed Process Map for Clinical Workflow of a New Biology-guided Radiotherapy (BgRT) Machine”
  • 2768 “Feasibility of Biology-Guided Radiotherapy for Pancreatic Tumors: An Assessment of Normalized Target SUV”

Monday, Oct 26, 12:20 PM Physics 06 – Imaging and Response Assessment:

  • SS 21 – “Increased 18F-FDG Metabolic Activity During Lung SBRT Predicts Risk of Disease Progression: Results from a Prospective Study of Serial Inter-Fraction PET/CTs”

Tuesday, Oct 27:

  • 3:15 PM QP-19 – Physics – Motion Management “Feasibility of Biology-guided Radiotherapy (BgRT) Targeting FDG Avid Liver Metastases”
  • 2:00 PM 2268 PV 06 Poster “FDG-PET Metrics in Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis”
  • 2:00 PM 2258 PV 06 Poster “Prognostic Value of FDG-PET Metrics for Advanced NSCLC Patients Treated with First-line Immunotherapy”

*The RefleXion X1 BgRT capability requires 510(k) clearance; this feature is not available for sale.

For more information: www.reflexion.com

Related Content

During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

Getty Images

News | Prostate Cancer | November 18, 2020
November 18, 2020 — ...
Minimizing delays to treatment could improve cancer survival rates, say researchers

Getty Images

News | Radiation Oncology | November 10, 2020
November 10, 2020 — People whose treatment for cancer is delayed by even one month have in many cases a 6 to 13% high
In this retrospective cohort study of men with low-risk prostate cancer followed up for a median of 7.6 years, African American men, compared with non-Hispanic White men, had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment, but not metastasis or prostate cancer–specific mortality

Getty Images

News | Prostate Cancer | November 04, 2020
November 4, 2020 — Previous studies have shown that African American men are 2.4 times as likely to die from...
Metastasis-free survival is a strong surrogate endpoint for overall survival over biochemical failure for men receiving salvage radiotherapy for recurrent prostate cancer

Getty Images

News | Prostate Cancer | November 02, 2020
November 2, 2020 — An analysis of the...
Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer. Image courtesy of the American College of Surgeons

Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer. Image courtesy of the American College of Surgeons

News | Radiation Therapy | November 02, 2020
November 2, 2020 — A nonsurgical treatment option for...